Home/Pipeline/seRNA 001

seRNA 001

Hepatocellular Carcinoma (HCC)

PreclinicalActive

Key Facts

Indication

Hepatocellular Carcinoma (HCC)

Phase

Preclinical

Status

Active

Company

SRTD biotech

About SRTD biotech

SRTD Biotech is a private, preclinical-stage biotech developing a proprietary 'RNA pro-drug' platform termed seRNA (selectively expressed RNA). The technology merges RNA interference for cell-specific targeting with mRNA for effector molecule expression, delivered via proprietary lipid nanoparticles (fLNPs). The company's initial pipeline focuses on oncology (HCC, glioblastoma, lung cancer), with plans to expand into viral and autoimmune diseases, aiming to overcome the off-target side effects common to many existing therapies.

View full company profile

Therapeutic Areas

Oncology Autoimmune Diseases Viral Diseases

Other Hepatocellular Carcinoma (HCC) Drugs

Drug	Company	Phase	Status
ADI-PEG 20 (pegargiminase)	Polaris Pharma	Phase 2/3	Active
Fostroxacitabine bralpamide (MIV-818)	Medivir	Phase 2a	Active
Nelitolimod (SD-101) via PEDD™ + systemic checkpoint inhibitors	TriSalus Life Sciences	Phase 1/2	Active, not recruiting
YntraDose	BetaGlue Therapeutics	Pre-clinical	Active
Seravue® (Diagnostic Assay)	ImCare Biotech	Development	Active
BC3402 + IMFINZI	BioCity Biopharma	Phase 1b/2	Collaboration with AstraZeneca, first patient dosed (2023)
ZW251	Zymeworks	Phase 1	Active
TTI-101	Tvardi Therapeutics	Phase 1b/2	Active